drugset / Trial / NCT00992849
Bevacizumab for the Treatment of Corneal Neovascularization
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the current study is to assess the efficacy and safety of the inhibitory effect of bevacizumab (Avastin) with different routes including topical and subconjunctival application on corneal neovascularization in the human eyes.
Timeline
- Start
- 2009-05
- Primary completion
- 2010-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg | Topical |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/ml | Topical |